Clinical Trials Sponsored by Moffitt Cancer Center P2C

Total 591 results

H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Terminated

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
ESP Pharma

Terminated

Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

Acute Myeloid Leukemia (AML)

United States
H. Lee Moffitt Cancer Center and Research Institute
Schering-Plough

Terminated

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

Brain Metastases

United States
H. Lee Moffitt Cancer Center and Research Institute
Endo Pharmaceuticals

Completed

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Terminated

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Non-Hodgkin's Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Aventis Pharmaceuticals

Terminated

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

Esophageal Adenocarcinomas | Adenocarcinomas of the Gastroesophageal Junction

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

Erlotinib Study for Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Metastatic Pancreatic Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer; National Comprehensive Cancer Network

Completed

A Study of Axitinib in Advanced Carcinoid Tumors

Carcinoid Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network; Cephalon

Terminated

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

Brain Metastases

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Upjohn

Completed

Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)

Lymphoma | Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); GlaxoSmithKline

Completed

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Pfizer

Completed

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

Neoplasms, Advanced

United States
H. Lee Moffitt Cancer Center and Research Institute
Cancer and Aging Research Group

Recruiting

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Lymphoma | Leukemia | Myeloma

United States
Memgen, Inc.
H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute

Recruiting

MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Cancer | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); AstraZeneca

Terminated

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Oklahoma

Recruiting

Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV/AIDS (ProjectENDIT)

Smoking Cessation | HIV

Cambodia
New Mexico Cancer Care Alliance
Ohio State University Comprehensive Cancer Center; H. Lee Moffitt Cancer Center...

Recruiting

Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer (TCCP)

Cancer | Cancer Risk

United States
H. Lee Moffitt Cancer Center and Research Institute
Patient-Centered Outcomes Research Institute

Completed

Navigator Guided e-Psychoeducational Intervention

Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Squamous Cell Carcinoma of Head and Neck | Metastatic Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
The Shulas' Foundation

Recruiting

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)

Triple Negative Breast Cancer | HER2-negative Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
EUSA Pharma, Inc.

Recruiting

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Large Granular Lymphocyte Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Recruiting

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

MDS | Myeloproliferative Neoplasm | Chronic Neutrophilic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Recruiting

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Myeloproliferative Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
Advanced Accelerator Applications

Recruiting

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Neuroendocrine Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | Colon Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Active, not recruiting

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

Metastatic Breast Cancer | Brain Metastases

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Active, not recruiting

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Prostate Cancer | Prostate Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
TG Therapeutics, Inc.

Terminated

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline; Oncovir, Inc.

Terminated

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

Multiple Myeloma | Plasma Cell Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
University of Florida

Completed

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

Soft Tissue Sarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Roche Pharma AG

Completed

Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer

Colorectal Cancer

United States, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
BioNumerik Pharmaceuticals, Inc.

Terminated

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

Malignant Melanoma

United States
ProCertus BioPharm, Inc
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

Alopecia | Radiodermatitis

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Janssen Pharmaceuticals

Terminated

A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer

Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Chiron Corporation

Completed

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

Kidney Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Parke-Davis

Completed

CI-994 in Treating Patients With Advanced Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Aventis Pharmaceuticals

Completed

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Blueprint Medicines Corporation

Recruiting

Avapritinib With Decitabine in Patients With SM-AHN

Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Recruiting

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Myelodysplastic Syndromes | Anemia | Myeloproliferative Neoplasm

United States
Modulation Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Uveal Melanoma | Metastatic

United States
H. Lee Moffitt Cancer Center and Research Institute
Anixa Biosciences, Inc.

Recruiting

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

Ovarian Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Progenics Pharmaceuticals, Inc.

Recruiting

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Recurrent Prostate Cancer | Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
OncoSec Medical Incorporated

Active, not recruiting

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Secura Bio, Inc.

Active, not recruiting

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloma | Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Extensive-stage Small Cell Lung Cancer

United States

Clinical Trials Sponsored by Moffitt Cancer Center P2C

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations